Bufalin has demonstrated its ability to modulate anti-tumor immunity by inhibiting the expression of nuclear factor-κB (NF-κB) p50, leading to an increase in p65–p50 heterodimerization. The gene discussed is NFKB1; the disease is neoplasm.